Stock VIRI VIRIOS THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Virios Therapeutics, Inc.

Equities

VIRI

US92829J1043

Market Closed - Nasdaq
Other stock markets
 21:30:01 10/05/2024 BST 		5-day change 1st Jan Change
0.3549 USD -4.75% Intraday chart for Virios Therapeutics, Inc. -13.75% -38.28%
05-09 Transcript : Virios Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024
05-09 Virios Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
AQ
Transcript : Virios Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024
Virios Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
AQ
Virios Therapeutics to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024
AQ
Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID
AQ
Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results
AQ
Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones
AQ
Virios Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
CI
Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results
AQ
Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones
AQ
Virios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVID
AQ
Virios Therapeutics Announces Plans to Advance Development of Imc-2 as Treatment for Symptoms Associated with Long-Covid
CI
Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID
CI
Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID
AQ
Virios Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Transcript : Virios Therapeutics, Inc., Q3 2023 Earnings Call, Nov 13, 2023
Virios Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
AQ
Virios Therapeutics to Report Third Quarter 2023 Financial Results on Monday, November 13, 2023
AQ
Thinking about buying stock in Aware, Virios Therapeutics, Bit Brother, Confluent, or Blue Star Foods?
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. VIRI Stock
  4. News Virios Therapeutics, Inc.